Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: A forty‐eight–week randomized, double‐blind trial

Maurice E.C. Jeurissen, Agnes M.Th. Boerbooms, Levinus B.A. van de Putte, Wim H. Doesburg, Jan Mulder, Johannes J. Rasker, Marijn W.M. Kruijsen, Joost F. Haverman, Henk J. van Beusekom, Wim Hissink Muller, Marcel J.A.M. Franssen, Dirk‐Jan R.A.M. de Rooy

Research output: Contribution to journalArticleAcademicpeer-review

92 Citations (Scopus)
1 Downloads (Pure)

Abstract

We conducted a double‐blind, randomized trial comparing azathioprine (AZA) and methotrexate (MTX) in the treatment of patients with rheumatoid arthritis in whom parenteral gold and/or D‐penicillamine treatment had been unsuccessful. Patients were randomly assigned to receive either AZA (100 mg daily) or oral MTX (7.5 mg weekly). After 8 weeks, the dosage was increased depending on the clinical improvement. Sixty‐four patients were followed up for 48 weeks (33 AZA, 31 MTX). Comparison of values at week 24 with baseline values revealed significant improvement in 12 of 13 disease variables in the MTX group and in 6 of 13 in the AZA group. Comparison between the 2 treatment groups at 24 weeks, by area‐under‐the‐curve analysis, showed significantly more improvement in the MTX group in terms of the swollen joint count, pain score, erythrocyte sedimentation rate, C‐reactive protein level, hemoglobin level, thrombocyte level, and disease activity score. A significant overall clinical improvement (disease activity score) was found in 7 of 20 patients treated with AZA and 18 of 30 patients treated with MTX after 24 weeks of therapy, and in 6 of 12 AZA‐treated patients and 19 of 25 MTX‐treated patients after 48 weeks. The number of withdrawals due to side effects was significantly higher in the AZA group. After 48 weeks, only 12 patients from the AZA group (36%), but 25 from the MTX group (81%), were still using the initial drug. These results demonstrate MTX to be superior to AZA in the treatment of rheumatoid arthritis, with a more rapid clinical improvement which is sustained after 1 year, accompanied by a lower rate of serious adverse reactions.

Original languageEnglish
Pages (from-to)961-972
Number of pages12
JournalArthritis & rheumatism
Volume34
Issue number8
DOIs
Publication statusPublished - 1 Aug 1991
Externally publishedYes

Fingerprint

Azathioprine
Methotrexate
Rheumatoid Arthritis
Therapeutics
Blood Sedimentation
Arthralgia
Gold
Hemoglobins
Blood Platelets
Pharmaceutical Preparations

Cite this

Jeurissen, M. E. C., Boerbooms, A. M. T., van de Putte, L. B. A., Doesburg, W. H., Mulder, J., Rasker, J. J., ... de Rooy, DJ. R. A. M. (1991). Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: A forty‐eight–week randomized, double‐blind trial. Arthritis & rheumatism, 34(8), 961-972. https://doi.org/10.1002/art.1780340805
Jeurissen, Maurice E.C. ; Boerbooms, Agnes M.Th. ; van de Putte, Levinus B.A. ; Doesburg, Wim H. ; Mulder, Jan ; Rasker, Johannes J. ; Kruijsen, Marijn W.M. ; Haverman, Joost F. ; van Beusekom, Henk J. ; Muller, Wim Hissink ; Franssen, Marcel J.A.M. ; de Rooy, Dirk‐Jan R.A.M. / Methotrexate versus azathioprine in the treatment of rheumatoid arthritis : A forty‐eight–week randomized, double‐blind trial. In: Arthritis & rheumatism. 1991 ; Vol. 34, No. 8. pp. 961-972.
@article{cbbd29113caa4941a52f82d74f3fe231,
title = "Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: A forty‐eight–week randomized, double‐blind trial",
abstract = "We conducted a double‐blind, randomized trial comparing azathioprine (AZA) and methotrexate (MTX) in the treatment of patients with rheumatoid arthritis in whom parenteral gold and/or D‐penicillamine treatment had been unsuccessful. Patients were randomly assigned to receive either AZA (100 mg daily) or oral MTX (7.5 mg weekly). After 8 weeks, the dosage was increased depending on the clinical improvement. Sixty‐four patients were followed up for 48 weeks (33 AZA, 31 MTX). Comparison of values at week 24 with baseline values revealed significant improvement in 12 of 13 disease variables in the MTX group and in 6 of 13 in the AZA group. Comparison between the 2 treatment groups at 24 weeks, by area‐under‐the‐curve analysis, showed significantly more improvement in the MTX group in terms of the swollen joint count, pain score, erythrocyte sedimentation rate, C‐reactive protein level, hemoglobin level, thrombocyte level, and disease activity score. A significant overall clinical improvement (disease activity score) was found in 7 of 20 patients treated with AZA and 18 of 30 patients treated with MTX after 24 weeks of therapy, and in 6 of 12 AZA‐treated patients and 19 of 25 MTX‐treated patients after 48 weeks. The number of withdrawals due to side effects was significantly higher in the AZA group. After 48 weeks, only 12 patients from the AZA group (36{\%}), but 25 from the MTX group (81{\%}), were still using the initial drug. These results demonstrate MTX to be superior to AZA in the treatment of rheumatoid arthritis, with a more rapid clinical improvement which is sustained after 1 year, accompanied by a lower rate of serious adverse reactions.",
author = "Jeurissen, {Maurice E.C.} and Boerbooms, {Agnes M.Th.} and {van de Putte}, {Levinus B.A.} and Doesburg, {Wim H.} and Jan Mulder and Rasker, {Johannes J.} and Kruijsen, {Marijn W.M.} and Haverman, {Joost F.} and {van Beusekom}, {Henk J.} and Muller, {Wim Hissink} and Franssen, {Marcel J.A.M.} and {de Rooy}, {Dirk‐Jan R.A.M.}",
year = "1991",
month = "8",
day = "1",
doi = "10.1002/art.1780340805",
language = "English",
volume = "34",
pages = "961--972",
journal = "Arthritis & rheumatism",
issn = "0004-3591",
publisher = "Wiley",
number = "8",

}

Jeurissen, MEC, Boerbooms, AMT, van de Putte, LBA, Doesburg, WH, Mulder, J, Rasker, JJ, Kruijsen, MWM, Haverman, JF, van Beusekom, HJ, Muller, WH, Franssen, MJAM & de Rooy, DJRAM 1991, 'Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: A forty‐eight–week randomized, double‐blind trial' Arthritis & rheumatism, vol. 34, no. 8, pp. 961-972. https://doi.org/10.1002/art.1780340805

Methotrexate versus azathioprine in the treatment of rheumatoid arthritis : A forty‐eight–week randomized, double‐blind trial. / Jeurissen, Maurice E.C.; Boerbooms, Agnes M.Th.; van de Putte, Levinus B.A.; Doesburg, Wim H.; Mulder, Jan; Rasker, Johannes J.; Kruijsen, Marijn W.M.; Haverman, Joost F.; van Beusekom, Henk J.; Muller, Wim Hissink; Franssen, Marcel J.A.M.; de Rooy, Dirk‐Jan R.A.M.

In: Arthritis & rheumatism, Vol. 34, No. 8, 01.08.1991, p. 961-972.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Methotrexate versus azathioprine in the treatment of rheumatoid arthritis

T2 - A forty‐eight–week randomized, double‐blind trial

AU - Jeurissen, Maurice E.C.

AU - Boerbooms, Agnes M.Th.

AU - van de Putte, Levinus B.A.

AU - Doesburg, Wim H.

AU - Mulder, Jan

AU - Rasker, Johannes J.

AU - Kruijsen, Marijn W.M.

AU - Haverman, Joost F.

AU - van Beusekom, Henk J.

AU - Muller, Wim Hissink

AU - Franssen, Marcel J.A.M.

AU - de Rooy, Dirk‐Jan R.A.M.

PY - 1991/8/1

Y1 - 1991/8/1

N2 - We conducted a double‐blind, randomized trial comparing azathioprine (AZA) and methotrexate (MTX) in the treatment of patients with rheumatoid arthritis in whom parenteral gold and/or D‐penicillamine treatment had been unsuccessful. Patients were randomly assigned to receive either AZA (100 mg daily) or oral MTX (7.5 mg weekly). After 8 weeks, the dosage was increased depending on the clinical improvement. Sixty‐four patients were followed up for 48 weeks (33 AZA, 31 MTX). Comparison of values at week 24 with baseline values revealed significant improvement in 12 of 13 disease variables in the MTX group and in 6 of 13 in the AZA group. Comparison between the 2 treatment groups at 24 weeks, by area‐under‐the‐curve analysis, showed significantly more improvement in the MTX group in terms of the swollen joint count, pain score, erythrocyte sedimentation rate, C‐reactive protein level, hemoglobin level, thrombocyte level, and disease activity score. A significant overall clinical improvement (disease activity score) was found in 7 of 20 patients treated with AZA and 18 of 30 patients treated with MTX after 24 weeks of therapy, and in 6 of 12 AZA‐treated patients and 19 of 25 MTX‐treated patients after 48 weeks. The number of withdrawals due to side effects was significantly higher in the AZA group. After 48 weeks, only 12 patients from the AZA group (36%), but 25 from the MTX group (81%), were still using the initial drug. These results demonstrate MTX to be superior to AZA in the treatment of rheumatoid arthritis, with a more rapid clinical improvement which is sustained after 1 year, accompanied by a lower rate of serious adverse reactions.

AB - We conducted a double‐blind, randomized trial comparing azathioprine (AZA) and methotrexate (MTX) in the treatment of patients with rheumatoid arthritis in whom parenteral gold and/or D‐penicillamine treatment had been unsuccessful. Patients were randomly assigned to receive either AZA (100 mg daily) or oral MTX (7.5 mg weekly). After 8 weeks, the dosage was increased depending on the clinical improvement. Sixty‐four patients were followed up for 48 weeks (33 AZA, 31 MTX). Comparison of values at week 24 with baseline values revealed significant improvement in 12 of 13 disease variables in the MTX group and in 6 of 13 in the AZA group. Comparison between the 2 treatment groups at 24 weeks, by area‐under‐the‐curve analysis, showed significantly more improvement in the MTX group in terms of the swollen joint count, pain score, erythrocyte sedimentation rate, C‐reactive protein level, hemoglobin level, thrombocyte level, and disease activity score. A significant overall clinical improvement (disease activity score) was found in 7 of 20 patients treated with AZA and 18 of 30 patients treated with MTX after 24 weeks of therapy, and in 6 of 12 AZA‐treated patients and 19 of 25 MTX‐treated patients after 48 weeks. The number of withdrawals due to side effects was significantly higher in the AZA group. After 48 weeks, only 12 patients from the AZA group (36%), but 25 from the MTX group (81%), were still using the initial drug. These results demonstrate MTX to be superior to AZA in the treatment of rheumatoid arthritis, with a more rapid clinical improvement which is sustained after 1 year, accompanied by a lower rate of serious adverse reactions.

UR - http://www.scopus.com/inward/record.url?scp=0025912605&partnerID=8YFLogxK

U2 - 10.1002/art.1780340805

DO - 10.1002/art.1780340805

M3 - Article

VL - 34

SP - 961

EP - 972

JO - Arthritis & rheumatism

JF - Arthritis & rheumatism

SN - 0004-3591

IS - 8

ER -